Salvage Lymphadenectomy as a Treatment of Prostate Cancer Recurrence

Author Info

Donghua Xie Yanda LU Di Gu Ming Lei Cong Cai Wen Zhong Defeng Qi Wenqi Wu Yongda Liu Guohua Zeng

Corresponding Author

Guohua Zeng
Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Urology, Guangdong Key Laboratory of Urology, Guangzhou, Guangdong, China

A B S T R A C T

Biochemical recurrence (BCR) occurs up to 40% of men who had radical prostatectomy for localized prostate cancer. Regional nodes are usually involved in these cases. Salvage lymphadenectomy (sLND) has been advocated in patients with 'node-only' metastasis with biochemical recurrence, following a definitive treatment of primary prostate cancer. In general, limited case number was reported for each previous study. Four relatively larger reports so far with the highest case number of 189. One randomized controlled study has been completed so far at Phase II level. Salvage LND seems to be safe with relatively low incidence of complications without perioperative mortality. It may postpone adjuvant therapy in selected cases, avoiding systemic side effects and possibly reducing the cost. However, long-term outcome is not very encouraging.

Article Info

Article Type

Review Article

Publication history

Received: Sat 16, Jan 2021
Accepted: Tue 09, Feb 2021
Published: Thu 11, Mar 2021

Copyright

© 2023 Guohua Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.GSCR.2021.01.03